1231-P: Dapagliflozin (DAPA) in Type 1 Diabetes (T1D): Pooled Outcomes from DEPICT-1 and -2

DEPICT-1 and -2 (NCT02268214, NCT02460978) were near identical studies assessing DAPA 5 and 10 mg as add-on to insulin (INS) in T1D. Here we present an analysis of the pooled population from the two studies. Safety data were available for 548, 566 and 532 patients (pts) in the DAPA 5 mg, 10 mg and placebo (PBO) groups, respectively and efficacy data for 530, 529 and 532 pts in each group, respectively. Baseline characteristics were similar...